BRIEF-Hemispherx Biopharma gets approval of NDA to treat chronic fatigue syndrome
Aug 23 (Reuters) - Hemispherx Biopharma Inc:
* Received approval of NDA in argentine republic for treatment of severe myalgic encephalomyelitis/chronic fatigue syndrome
* Says rintatolimod will be marketed by GP Pharm, Hemispherx's commercial partner in Latin America Source text for Eikon: Further company coverage:
© Thomson Reuters 2017 All rights reserved.